Castle Biosciences公司产品介绍 - Castle Biosciences公司在2024年AAD年会上将分享其皮肤病学基因表达谱（GEP）测试组合的数据[1] - Castle Biosciences公司的DecisionDx-Melanoma测试与未经测试的患者相比，与改善黑色素瘤特异性存活率相关[3] - Castle Biosciences公司的DecisionDx-SCC测试在高危皮肤鳞状细胞癌（cSCC）患者中得到一致利用，为患者提供个性化的治疗方案[5] Castle Biosciences公司测试应用 - MyPath Melanoma测试通过RNA基因表达谱（GEP）测试，为侵袭性黑色素瘤患者提供准确的诊断结果[8] - DecisionDx-Melanoma测试已被超过15万次用于诊断皮肤黑色素瘤患者，显示其在患者生存率方面的临床价值[9] - DecisionDx-SCC测试可预测皮肤鳞状细胞癌转移的个体风险，为患者提供风险适当的管理建议[10] Castle Biosciences公司创新产品 - MyPath Melanoma测试可帮助皮肤病理学家和皮肤科医生准确诊断难以分类的黑色素细胞病变[11] - Castle Biosciences公司致力于通过创新测试改善患者护理，目前的产品组合包括皮肤癌、Barrett食管、精神健康状况和葡萄膜黑色素瘤测试[12]

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new multi-center performance study of its DecisionDx-SCC risk stratification test. The study, published in Dermatology and Therapy and available here, analyzed the independent performance of DecisionDx-SCC from risk factors and traditional staging systems (i.e., Brigham and Women’s Hospital (BWH) and American Joint Com ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Founder & Director Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Brandon Kramer - Guggenheim Securities Sung Ji Nam - Scotiabank Tom Peterson - Baird Jacob Krahenbuhl - Stephens Thomas Flaten - Lake Street Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarte ...

Castle Biosciences, Inc. (CSTL) reported $66.12 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 72.5%. EPS of -$0.10 for the same period compares to -$0.78 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $51.32 million, representing a surprise of +28.85%. The company delivered an EPS surprise of +88.10%, with the consensus EPS estimate being -$0.84.While investors scrutinize revenue and earnings changes year-over-year and how they ...

财务表现 - Castle Biosciences, Inc.在上一个季度每股亏损为$0.10，超过了Zacks Consensus Estimate的每股亏损$0.84[1] - Castle Biosciences, Inc.在过去四个季度中，三次超过了市场预期的每股收益[2] - Castle Biosciences, Inc.在2023年12月份的季度实现了6600万美元的营收，超过了Zacks Consensus Estimate的2885%[3] - Castle Biosciences, Inc.的当前一致预期每股亏损为-$0.82，营收为5075万美元，当前财年每股亏损为-$2.99，营收为2.2713亿美元[9] 股价表现 - Castle Biosciences, Inc.股价自年初以来上涨了16.3%，超过了标普500指数的6.5%[5] 行业前景 - 医疗-生物医学和遗传学行业的前景对公司股价表现有重要影响，该行业目前在Zacks行业排名中处于前34%[10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in Cancers1 demonstrating that DecisionDx-Melanoma provided significantly better risk stratification than American Joint Committee on Cancer 8th Edition (AJCC8) staging in patients with stage I cutaneous melanoma (CM). This study reports the results of two large stage I cohorts, including 5,651 patients from the ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast o ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study1 in The Journal of Clinical and Aesthetic Dermatology (JCAD) which found that using its DecisionDx-SCC test to guide ART decisions for patients with SCC could result in substantial Medicare healthcare savings of up to approximately $972 million annually. “The implications of this study are significant, as ...

Castle Biosciences产品展示 - Castle Biosciences将在2024年冬季临床皮肤病学会议上展示其皮肤病学产品组合的新数据[1] DecisionDx-Melanoma基因表达谱测试 - DecisionDx-Melanoma基因表达谱测试结果与临床和病理因素结合，为皮肤癌患者提供更个性化、精准的肿瘤复发风险评估[3] DecisionDx-SCC基因表达谱测试 - DecisionDx-SCC基因表达谱测试可独立提高对低分期肿瘤转移风险的识别，为临床决策提供更准确的风险评估[3]